Cancer News, Research & Analysis
Time-sensitive and reliable coverage of pharmaceutical industry
developments, clinical trials, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €750/£675 a year per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna head office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients
Patients can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. Alcohol and Cancer Risk: Most Americans Aren't Aware of the Link
- 2. 'Something Good' After Tragic Loss: Donating Brain Cancer Tissue
- 3. Colorectal Cancer: Healthy Plant-Based Diet May Decrease Risk By Up to 22%
- 4. Le groupe Menarini présente les résultats mis à jour de l'essai pivot de phase 3 EMERALD au Symposium sur le cancer du sein à San Antonio (SABCS) de 2022, qui démontrent que la SSP de l'élacestrant augmente avec la durée du traitement antérieur par CDK4/6i dans les cas de cancer ER+/HER2- en situation métastatique
- 5. Holiday Drinking Can Hurt Your Heart. Here Are Tips to Stay Healthy.
- 6. UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- 7. Global Lung Cancer Screening Software Market Report 2022: Growing Awareness about Screening Programs Presents Opportunities - ResearchAndMarkets.com
- 8. JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential
- 9. Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention
- 10. Henlius and Innovent/Lilly: A Tale of Two PD-1 Candidates
Last updated at 21:55 GMT
Hot News Makers
Health/Pharma Companies
-
20769.77
-
6250.89
-
3914.39
-
2563.06
-
2430.68
-
2041.49
-
1914.48
-
1597.54
-
1397.22
-
1009.14
Last updated at 21:10 GMT